Cargando…

Dexamethasone- cyclophosphamide pulse in collagen vascular diseases: An observation

BACKGROUND: Treatment of collagen vascular diseases like systemic sclerosis, dermatomyositis, systemic lupus erythematosus (SLE) and even overlap syndromes has been difficult since long. Monumental success of dexamethasone-cyclophosphamide pulse (DCP) in pemphigus has prompted many a dermatologist t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Sudip, Giri, Parag Prasun, Roy, Aloke Kr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications Pvt Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481802/ https://www.ncbi.nlm.nih.gov/pubmed/23130206 http://dx.doi.org/10.4103/2229-5178.79858

Ejemplares similares

A Comparative Study to Evaluate the Efficacy and Cost of Rituximab versus Dexamethasone Cyclophosphamide Pulse in Patients of Pemphigus Vulgaris
por: Das, Sudip, et al.
Publicado: (2021)

MUCOSAL PATCH ON ANUS: A RARE SEQUEL OF SODOMY
por: Das, Sudip, et al.
Publicado: (2008)

DEXAMETHASONE–CYCLOPHOSPHAMIDE PULSE THERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS
por: Viswanath, Vishalakshi, et al.
Publicado: (2010)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy
por: Annavarajula, S. K., et al.
Publicado: (2011)

Dexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study()
por: Fontenelle, Ludmilla Figueiredo, et al.
Publicado: (2023)

A Six-Month Prospective Study to Find Out the Treatment Outcome, Prognosis and Offending Drugs in Toxic Epidermal Necrolysis from an Urban Institution in Kolkata
por: Das, Sudip, et al.
Publicado: (2013)

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
por: Brennan, Xavier, et al.
Publicado: (2022)

Peyronie's Disease Treated with Oral Weekly Dexamethasone and Continuous Low-dose Cyclophosphamide
por: Gupta, Ramji, et al.
Publicado: (2014)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy
por: Venkatesh, Pradeep, et al.
Publicado: (2015)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
por: Park, Hyunkyung, et al.
Publicado: (2022)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Pulse cyclophosphamide therapy for steroid-resistant focal segmental glomerulosclerosis in children
por: Al Salloum, Abdullah A.
Publicado: (2004)

Bortezomib/cyclophosphamide/dexamethasone: Reinfection in the form of COVID-19 pneumonia : case report
Publicado: (2021)

Epidural Extramedullary Plasmacytoma Successfully Treated with Surgical Excision and Bortezomib, Cyclophosphamide and Dexamethasone
por: MARTIO, ARTUR EDUARDO, et al.
Publicado: (2023)

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
por: Kastritis, E, et al.
Publicado: (2017)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma
por: Lee, Seung-Shin, et al.
Publicado: (2019)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
por: Wang, Di, et al.
Publicado: (2021)

Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
por: Rosenbaum, Cara A., et al.
Publicado: (2022)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats
por: Lon, Hoi-Kei, et al.
Publicado: (2015)

Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation
por: Felici, S, et al.
Publicado: (2013)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

CD13/aminopeptidase N in collagen vascular diseases
por: Dan, Hirohumi, et al.
Publicado: (2003)

Neurological Manifestations of Collagen-Vascular Disease
por: Miller, Henry
Publicado: (1966)

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy
por: Philip, Rajeev, et al.
Publicado: (2013)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
por: Auner, Holger W., et al.
Publicado: (2022)

Pediatric inflammatory multisystem syndrome (PIMS) presenting with retropharyngeal phlegmon mimicking Kawasaki disease
por: Gupta, Purbasha, et al.
Publicado: (2021)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens
por: Kubota, Kaoru, et al.
Publicado: (2016)

Successful treatment of type B insulin resistance with mixed connective tissue disease by pulse glucocorticoids and cyclophosphamide
por: Yang, Hongbo, et al.
Publicado: (2017)

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
por: Brown, Sarah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j6n22d7dt8avsp38b1i159r0hs